Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 258

1.

The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor.

Isabel E, Bateman KP, Chauret N, Cromlish W, Desmarais S, Duong LT, Falgueyret JP, Gauthier JY, Lamontagne S, Lau CK, Léger S, LeRiche T, Lévesque JF, Li CS, Massé F, McKay DJ, Mellon C, Nicoll-Griffith DA, Oballa RM, Percival MD, Riendeau D, Robichaud J, Rodan GA, Rodan SB, Seto C, Thérien M, Truong VL, Wesolowski G, Young RN, Zamboni R, Black WC.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):887-92. doi: 10.1016/j.bmcl.2009.12.083. Epub 2009 Dec 28.

PMID:
20061146
2.

Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glands.

Schmidt A, Harada S, Kimmel DB, Bai C, Chen F, Rutledge SJ, Vogel RL, Scafonas A, Gentile MA, Nantermet PV, McElwee-Witmer S, Pennypacker B, Masarachia P, Sahoo SP, Kim Y, Meissner RS, Hartman GD, Duggan ME, Rodan GA, Towler DA, Ray WJ.

J Biol Chem. 2009 Dec 25;284(52):36367-76. doi: 10.1074/jbc.M109.049734. Epub 2009 Oct 21.

3.

Control of rat tail skin temperature regulation by estrogen receptor-beta selective ligand.

Opas EE, Scafonas A, Nantermet PV, Wilkening RR, Birzin ET, Wilkinson H, Colwell LF, Schaeffer JM, Towler DA, Rodan GA, Schmidt A.

Maturitas. 2009 Sep 20;64(1):46-51. doi: 10.1016/j.maturitas.2009.07.007. Epub 2009 Aug 12.

PMID:
19679413
4.

Bone density, strength, and formation in adult cathepsin K (-/-) mice.

Pennypacker B, Shea M, Liu Q, Masarachia P, Saftig P, Rodan S, Rodan G, Kimmel D.

Bone. 2009 Feb;44(2):199-207. doi: 10.1016/j.bone.2008.08.130. Epub 2008 Sep 19.

PMID:
18845279
5.

Agonist-like SERM effects on ERalpha-mediated repression of MMP1 promoter activity predict in vivo effects on bone and uterus.

Scafonas A, Reszka AA, Kimmel DB, Hou XS, Su Q, Birzin ET, Kim S, Chen HY, Tan Q, Roher SP, Dininno F, Hammond ML, Rodan GA, Towler DA, Schmidt A.

J Steroid Biochem Mol Biol. 2008 Jun;110(3-5):197-206. doi: 10.1016/j.jsbmb.2007.10.013. Epub 2008 Apr 20.

PMID:
18508261
6.

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.

Gauthier JY, Chauret N, Cromlish W, Desmarais S, Duong LT, Falgueyret JP, Kimmel DB, Lamontagne S, Léger S, LeRiche T, Li CS, Massé F, McKay DJ, Nicoll-Griffith DA, Oballa RM, Palmer JT, Percival MD, Riendeau D, Robichaud J, Rodan GA, Rodan SB, Seto C, Thérien M, Truong VL, Venuti MC, Wesolowski G, Young RN, Zamboni R, Black WC.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):923-8. doi: 10.1016/j.bmcl.2007.12.047. Epub 2008 Jan 15.

PMID:
18226527
7.

Involvement of alpha(v)beta3 integrins in osteoclast function.

Nakamura I, Duong LT, Rodan SB, Rodan GA.

J Bone Miner Metab. 2007;25(6):337-44. Epub 2007 Oct 25. Review.

PMID:
17968485
8.

Prostaglandin E2 (PGE2) increases the number of rat bone marrow osteogenic stromal cells (BMSC) via binding the EP4 receptor, activating sphingosine kinase and inhibiting caspase activity.

Weinreb M, Shamir D, Machwate M, Rodan GA, Harada S, Keila S.

Prostaglandins Leukot Essent Fatty Acids. 2006 Aug;75(2):81-90. Epub 2006 Aug 4.

PMID:
16890416
9.

M-CSF induces the stable interaction of cFms with alphaVbeta3 integrin in osteoclasts.

Elsegood CL, Zhuo Y, Wesolowski GA, Hamilton JA, Rodan GA, Duong LT.

Int J Biochem Cell Biol. 2006;38(9):1518-29. Epub 2006 Mar 2.

PMID:
16600665
10.

Preservation of thoracic spine microarchitecture by alendronate: comparison of histology and microCT.

Hordon LD, Itoda M, Shore PA, Shore RC, Heald M, Brown M, Kanis JA, Rodan GA, Aaron JE.

Bone. 2006 Mar;38(3):444-9. Epub 2005 Dec 19.

PMID:
16361121
11.

Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K.

Palmer JT, Bryant C, Wang DX, Davis DE, Setti EL, Rydzewski RM, Venkatraman S, Tian ZQ, Burrill LC, Mendonca RV, Springman E, McCarter J, Chung T, Cheung H, Janc JW, McGrath M, Somoza JR, Enriquez P, Yu ZW, Strickley RM, Liu L, Venuti MC, Percival MD, Falgueyret JP, Prasit P, Oballa R, Riendeau D, Young RN, Wesolowski G, Rodan SB, Johnson C, Kimmel DB, Rodan G.

J Med Chem. 2005 Dec 1;48(24):7520-34.

PMID:
16302794
12.

Antagonist-induced, activation function-2-independent estrogen receptor alpha phosphorylation.

Lipfert L, Fisher JE, Wei N, Scafonas A, Su Q, Yudkovitz J, Chen F, Warrier S, Birzin ET, Kim S, Chen HY, Tan Q, Schmidt A, Dininno F, Rohrer SP, Hammond ML, Rodan GA, Freedman LP, Reszka AA.

Mol Endocrinol. 2006 Mar;20(3):516-33. Epub 2005 Oct 13.

PMID:
16223974
13.

Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis.

Hayami T, Pickarski M, Zhuo Y, Wesolowski GA, Rodan GA, Duong LT.

Bone. 2006 Feb;38(2):234-43. Epub 2005 Sep 26.

PMID:
16185945
14.

Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy.

Leu CT, Luegmayr E, Freedman LP, Rodan GA, Reszka AA.

Bone. 2006 May;38(5):628-36. Epub 2005 Sep 26.

PMID:
16185944
15.

Mechanism of action of bisphosphonates.

Reszka AA, Rodan GA.

Curr Osteoporos Rep. 2003 Sep;1(2):45-52. Review.

PMID:
16036064
16.

Estrogenic control of thermoregulation in ERalphaKO and ERbetaKO mice.

Opas EE, Gentile MA, Kimmel DB, Rodan GA, Schmidt A.

Maturitas. 2006 Jan 20;53(2):210-6.

PMID:
15908148
17.

Trabecular bone microarchitecture after alendronate treatment of osteoporotic women.

Recker R, Masarachia P, Santora A, Howard T, Chavassieux P, Arlot M, Rodan G, Wehren L, Kimmel D.

Curr Med Res Opin. 2005 Feb;21(2):185-94. Erratum in: Curr Med Res Opin. 2005 Feb;21(2):324.

PMID:
15801989
18.

Nonpeptide alpha(v)beta3 antagonists: identification of potent, chain-shortened 7-oxo RGD mimetics.

Zartman AE, Duong LT, Fernandez-Metzler C, Hartman GD, Leu CT, Prueksaritanont T, Rodan GA, Rodan SB, Duggan ME, Meissner RS.

Bioorg Med Chem Lett. 2005 Mar 15;15(6):1647-50.

PMID:
15745815
19.

Cross-talk between an activator of nuclear receptors-mediated transcription and the D1 dopamine receptor signaling pathway.

Schmidt A, Vogel R, Rutledge SJ, Opas EE, Rodan GA, Friedman E.

Pharmacol Biochem Behav. 2005 Mar;80(3):379-85. Epub 2005 Jan 26.

PMID:
15740779
20.

Nitrogen-containing bisphosphonate mechanism of action.

Reszka AA, Rodan GA.

Mini Rev Med Chem. 2004 Sep;4(7):711-9. Review.

PMID:
15379639
21.

Nonpeptide alphavbeta3 antagonists. Part 11: discovery and preclinical evaluation of potent alphavbeta3 antagonists for the prevention and treatment of osteoporosis.

Coleman PJ, Brashear KM, Askew BC, Hutchinson JH, McVean CA, Duong LT, Feuston BP, Fernandez-Metzler C, Gentile MA, Hartman GD, Kimmel DB, Leu CT, Lipfert L, Merkle K, Pennypacker B, Prueksaritanont T, Rodan GA, Wesolowski GA, Rodan SB, Duggan ME.

J Med Chem. 2004 Sep 23;47(20):4829-37.

PMID:
15369386
22.

Nonpeptide alpha V beta 3 antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivative.

Breslin MJ, Duggan ME, Halczenko W, Hartman GD, Duong LT, Fernandez-Metzler C, Gentile MA, Kimmel DB, Leu CT, Merkle K, Prueksaritanont T, Rodan GA, Rodan SB, Hutchinson JH.

Bioorg Med Chem Lett. 2004 Sep 6;14(17):4515-8.

PMID:
15357983
23.

Nonpeptide alpha V beta 3 antagonists. Part 9: Improved pharmacokinetic profile through the use of an aliphatic, des-amide backbone.

Whitman DB, Askew BC, Duong LT, Fernandez-Metzler C, Halczenko W, Hartman GD, Hutchinson JH, Leu CT, Prueksaritanont T, Rodan GA, Rodan SB, Duggan ME.

Bioorg Med Chem Lett. 2004 Sep 6;14(17):4411-5.

PMID:
15357963
24.

Bone safety of long-term bisphosphonate treatment.

Rodan G, Reszka A, Golub E, Rizzoli R.

Curr Med Res Opin. 2004 Aug;20(8):1291-300. Review.

PMID:
15324532
25.

Rat tail skin temperature regulation by estrogen, phytoestrogens and tamoxifen.

Opas EE, Rutledge SJ, Vogel RL, Rodan GA, Schmidt A.

Maturitas. 2004 Aug 20;48(4):463-71.

PMID:
15283940
26.

The LATS2/KPM tumor suppressor is a negative regulator of the androgen receptor.

Powzaniuk M, McElwee-Witmer S, Vogel RL, Hayami T, Rutledge SJ, Chen F, Harada S, Schmidt A, Rodan GA, Freedman LP, Bai C.

Mol Endocrinol. 2004 Aug;18(8):2011-23. Epub 2004 May 6.

PMID:
15131260
27.
28.

Osteoclast formation, survival and morphology are highly dependent on exogenous cholesterol/lipoproteins.

Luegmayr E, Glantschnig H, Wesolowski GA, Gentile MA, Fisher JE, Rodan GA, Reszka AA.

Cell Death Differ. 2004 Jul;11 Suppl 1:S108-18.

29.

Non-peptide alpha v beta 3 antagonists. Part 7: 3-Substituted tetrahydro-naphthyridine derivatives.

Wang J, Breslin MJ, Coleman PJ, Duggan ME, Hunt CA, Hutchinson JH, Leu CT, Rodan SB, Rodan GA, Duong LT, Hartman GD.

Bioorg Med Chem Lett. 2004 Feb 23;14(4):1049-52.

PMID:
15013021
30.

Regulatory mechanism of osteoclast activation.

Nakamura I, Rodan GA, Duong LT.

J Electron Microsc (Tokyo). 2003;52(6):527-33. Review.

PMID:
14756240
31.

Non-peptide alpha(v)beta(3) antagonists: identification of potent, chain-shortened RGD mimetics that incorporate a central pyrrolidinone constraint.

Perkins JJ, Duong LT, Fernandez-Metzler C, Hartman GD, Kimmel DB, Leu CT, Lynch JJ, Prueksaritanont T, Rodan GA, Rodan SB, Duggan ME, Meissner RS.

Bioorg Med Chem Lett. 2003 Dec 15;13(24):4285-8.

PMID:
14643310
32.

Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis.

Hutchinson JH, Halczenko W, Brashear KM, Breslin MJ, Coleman PJ, Duong LT, Fernandez-Metzler C, Gentile MA, Fisher JE, Hartman GD, Huff JR, Kimmel DB, Leu CT, Meissner RS, Merkle K, Nagy R, Pennypacker B, Perkins JJ, Prueksaritanont T, Rodan GA, Varga SL, Wesolowski GA, Zartman AE, Rodan SB, Duggan ME.

J Med Chem. 2003 Oct 23;46(22):4790-8.

PMID:
14561098
33.

M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase.

Glantschnig H, Fisher JE, Wesolowski G, Rodan GA, Reszka AA.

Cell Death Differ. 2003 Oct;10(10):1165-77.

34.
35.

Osteoporosis and bisphosphonates.

Rodan GA, Reszka AA.

J Bone Joint Surg Am. 2003;85-A Suppl 3:8-12. No abstract available.

PMID:
12925603
36.

Control of osteoblast function and regulation of bone mass.

Harada S, Rodan GA.

Nature. 2003 May 15;423(6937):349-55. Review.

PMID:
12748654
37.

Receptor tyrosine kinases inhibit bone morphogenetic protein-Smad responsive promoter activity and differentiation of murine MC3T3-E1 osteoblast-like cells.

Nakayama K, Tamura Y, Suzawa M, Harada S, Fukumoto S, Kato M, Miyazono K, Rodan GA, Takeuchi Y, Fujita T.

J Bone Miner Res. 2003 May;18(5):827-35.

38.

Pathogenesis of osteoporosis.

Raisz LG, Rodan GA.

Endocrinol Metab Clin North Am. 2003 Mar;32(1):15-24. Review.

PMID:
12699290
39.

Preclinical evidence of normal bone with alendronate.

Hayes WC, Shea M, Rodan GA.

Int J Clin Pract Suppl. 1999 Apr;101:9-13. Review.

PMID:
12669735
40.

Preclinical safety profile of alendronate.

Peter C, Rodan GA.

Int J Clin Pract Suppl. 1999 Apr;101:3-8.

PMID:
12669734
41.

Bisphosphonate mechanism of action.

Reszka AA, Rodan GA.

Curr Rheumatol Rep. 2003 Feb;5(1):65-74. Review.

PMID:
12590887
42.

The development and function of the skeleton and bone metastases.

Rodan GA.

Cancer. 2003 Feb 1;97(3 Suppl):726-32. Review.

43.

PYK2 autophosphorylation, but not kinase activity, is necessary for adhesion-induced association with c-Src, osteoclast spreading, and bone resorption.

Lakkakorpi PT, Bett AJ, Lipfert L, Rodan GA, Duong LT.

J Biol Chem. 2003 Mar 28;278(13):11502-12. Epub 2003 Jan 3.

44.

Development of selective androgen receptor modulators and their therapeutic applications.

Chen F, Rodan GA, Schmidt A.

Zhonghua Nan Ke Xue. 2002;8(3):162-8. Review.

PMID:
12478835
45.

Non-peptide alpha(v)beta(3) antagonists. Part 5: identification of potent RGD mimetics incorporating 2-aryl beta-amino acids as aspartic acid replacements.

Brashear KM, Hunt CA, Kucer BT, Duggan ME, Hartman GD, Rodan GA, Rodan SB, Leu CT, Prueksaritanont T, Fernandez-Metzler C, Barrish A, Homnick CF, Hutchinson JH, Coleman PJ.

Bioorg Med Chem Lett. 2002 Dec 2;12(23):3483-6.

PMID:
12419389
46.

Bisphosphonates and primary hyperparathyroidism.

Rodan GA.

J Bone Miner Res. 2002 Nov;17 Suppl 2:N150-3. Review.

PMID:
12412793
47.

Bisphosphonate mechanism of action.

Rodan GA, Reszka AA.

Curr Mol Med. 2002 Sep;2(6):571-7. Review.

PMID:
12243249
48.

Mapping of MST1 kinase sites of phosphorylation. Activation and autophosphorylation.

Glantschnig H, Rodan GA, Reszka AA.

J Biol Chem. 2002 Nov 8;277(45):42987-96. Epub 2002 Sep 9.

49.

Non-peptide alpha(v)beta(3) antagonists. Part 4: potent and orally bioavailable chain-shortened RGD mimetics.

Coleman PJ, Askew BC, Hutchinson JH, Whitman DB, Perkins JJ, Hartman GD, Rodan GA, Leu CT, Prueksaritanont T, Fernandez-Metzler C, Merkle KM, Lynch R, Lynch JJ, Rodan SB, Duggan ME.

Bioorg Med Chem Lett. 2002 Sep 2;12(17):2463-5.

PMID:
12161158
50.

IL-1 regulates cytoskeletal organization in osteoclasts via TNF receptor-associated factor 6/c-Src complex.

Nakamura I, Kadono Y, Takayanagi H, Jimi E, Miyazaki T, Oda H, Nakamura K, Tanaka S, Rodan GA, Duong LT.

J Immunol. 2002 May 15;168(10):5103-9.

Supplemental Content

Support Center